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Abstract
Background: The cardioprotective effects of certain alcoholic beverages are partly related to
their polyphenol content, which may improve the vasodilatory reactivity of arteries. Effect of
cognac on coronary circulation, however, remains unknown. The purpose of this randomized
controlled cross-over study was to determine whether moderate doses of cognac improve
coronary reactivity as assessed with cold pressor testing (CPT) and coronary flow reserve (CFR)
measument.
Methods: Study group consisted of 23 subjects. Coronary flow velocity and epicardial diameter
was assessed using transthoracic echocardiography at rest, during CPT and adenosine infusion-
derived CFR measurements before drinking, after a moderate (1.2 ± 0.1 dl) and an escalating high
dose (total amount 2.4 ± 0.3 dl) of cognac. To explore the bioavailability of antioxidants, the
antioxidant contents of cognac was measured and the absorption from the digestive tract was
verified by plasma antioxidant capacity determination.
Results: Serum alcohol levels increased to 1.2 ± 0.2‰ and plasma antioxidant capacity from 301
± 43.9 μmol/l to 320 ± 25.0 μmol/l by 7.6 ± 11.8%, (p = 0.01) after high doses of cognac. There
was no significant change in flow velocity during CPT after cognac ingestion compared to control
day. CFR was 4.4 ± 0.8, 4.1 ± 0.9 (p = NS), and 4.5 ± 1.2 (p = NS) before drinking and after
moderate and high doses on cognac day, and 4.5 ± 1.4, and 4.0 ± 1.2 (p = NS) on control day.
Conclusion: Cognac increased plasma antioxidant capacity, but it had no effect on coronary
circulation in healthy young men.
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Introduction
Moderate consumption of alcohol is associated with
reduced coronary artery disease mortality [1,2]. The cardi-
oprotective effects of alcoholic beverages are partly related
to their polyphenol content, which may be associated
with improved vasodilatory reactivity of arteries [3,4]. A
moderate (ethanol 0.5 g/kg) [5] and a high dose of red
wine (ethanol 1.0 g/kg) has been shown to increase coro-
nary flow reserve (CFR), but pure vodka and white wine
had not such effect [3]. The effects of cognac on coronary
circulation, however, have not been evaluated, although
many elderly patients with coronary artery disease drink
habitually cognac to releave cardiac symptoms.
The beneficial endothelial effects of polyphenol contain-
ing beverages, such as red wine, have been attributed to
both ethanol and antioxidative polyphenols [6,7]. How-
ever, their relative contributions in vivo remain to be
established. Cognac is known to contain polyphenols [8],
but the bioavailability of the antioxidant content of
cognac has not been previously addressed.
Cold pressor test (CPT) and CFR measurements are widely
used methods to study coronary circulation [9-11].
Impairment of coronary artery reactivity as shown by
insufficient vasodilation, or vasoconstriction in CPT, or
decreased CFR occurs in various cardiovascular diseases,
such as hypertension [12], diabetes [13], hypercholestero-
lemia [14], coronary artery disease [15], and even in oth-
erwise healthy subjects with increasing waist to hip ratio
[16]. Abnormal response in these tests is related to impair-
ment in coronary vascular smooth muscle or endothelial
function or both [9].
The purpose of this randomized controlled cross-over
study was to determine with transthoracic echocardiogra-
phy whether cognac ingested in moderate or high doses
improve coronary vasodilatory responses in healthy
humans. We also studied the bioavailability of antioxi-
dants by determining the plasma antioxidant capacity.
Methods
Subjects and study protocol
The study included 23 healthy, non-smoking Finnish men
(mean age 23 ± 1.8 years, body mass index 24 ± 2.3 kg/m2,
total cholesterol 4.2 ± 0.8 mmol/l, HDL cholesterol 1.6 ±
0.41 mmol/l, LDL cholesterol 2.3 ± 0.65 mmol/l, triglyc-
erides 0.77 ± 0.21 mmol/l and plasma glucose 5.0 ± 0.46
mmol/l). None of the subjects were taking any medica-
tion. The study was carried out in accordance with the
Declaration of Helsinki (2000) of the World Medical
Association and approved by the Ethics Committee of the
Southwest Finland Health Care District. All subjects gave
their written informed consent. We calculated sample size
of 16 subjects with a known SD of 1.0 (for CFR) and an
assumed difference of 1.0 between the interventions (α =
0.05, β = 0.80). To deal with the loss of data during the
analysis, we enrolled 23 subjects.
Figure 1 outlines the study protocol. The subjects had an
overnight fast. They were instructed to avoid caffeine for
12 h, and alcohol for 36 h before the studies. There were
at least one week between the study days. The subjects
were assigned to take two escalating doses of cognac. A
moderate dose of cognac contained 0.5 g/kg of ethanol
and a high dose 1.0 g/kg. Accordingly, the full doses of
cognac were 2.4 ± 0.3 dl, respectively. CPT and CFR meas-
urements were performed before drinking and again 30
Study protocol Figure 1
Study protocol. The subjects ingested two escalating doses of cognac (one dose 1.2 ± 0.1 dl). Each dose of cognac contained 
ethanol 0.5 mg/kg, and accordingly, the full dose of ethanol was 1.0 g/kg. CFR was measured 30 min after each dose. As a con-
trol, CFR was measured in randomized cross-over design without beverage ingestion twice.Cardiovascular Ultrasound 2008, 6:25 http://www.cardiovascularultrasound.com/content/6/1/25
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minutes after each dose. As a control, the measurements
were assessed in a random cross-over design repeatedly
with 2 h interval when the subjects were not drinking.
Blood pressure and ECG were monitored at rest and
throughout the measurements. The rate pressure product
was calculated as systolic blood pressure multiplied by
heart rate.
Cognac
The concentration of phenolic substances of the study
cognac (Remy Martin VSOP, France) was determined
according to the Folin-Ciocalteau method [17] (Sigma, St.
Louis, MO). The total amount of phenolic substances
given to the subjects was 100 mg ± 10 mg, including
Ellagic acid 2.51 ± 0.28 mg, Hydroxybenzoic acid 0.70 ±
0.09 mg, Procyanidines (oligomers) 0.48 ± 0.06 mg,
Hydroxycinnamic acids 0.12 ± 0.02 mg. In addition, the
ability of the cognac to act as free radical scavengers
against 1,1-diphenyl-2-picrylhydrazyl radical (Extrasyn-
thèse, Genay, France) was tested spectrophotometrically
[18]. The free radical scavenger capacitiy of the cognac was
7.0 ± 2.7%.
Echocardiography
Coronary flow velocity and epicardial coronary artery
diameter were measured in the distal left anterior
descending coronary artery (LAD) with transthoracic
echocardiography using the Sequoia C 512 ultrasound
device (Acuson Inc., Mountain View, California, USA)
with a linear 8.0 MHz transducer. The distal LAD was
localized with color Doppler mapping using a modified
apical two-chamber view scanning the interventricular
sulcus as previously described [19]. The LAD flow velocity
profile was recorded using a pulsed wave Doppler with
angle correction. Moreover, the end-diastolic diameter of
the LAD was measured in 2D images at the end of expira-
tion from the largest distance between the luminal edges
from the black-white interface of the near and far walls
using ImageJ software (ImageJ 1.30 N, National institutes
of Health, USA) [20]. The flow velocity profiles and 2D
images of the LAD were obtained alternately at rest and
throughout adenosine infusion as previously described
(see Figures 2 and 3) [21]. Maximal mean diastolic veloc-
ities were used to calculate the percentage increase of cor-
onary flow velocity during CPT to baseline and coronary
flow velocity reserve (CFR) as previously described [19].
The variability of repeated CPT and CFR measurements
was moderate (CV 13.4 ± 10.4 and 11.4 ± 8.9%, respec-
tively), and the intra-observer variability was low (CV 3.0
± 2.0 and 2.6 ± 4.0%, respectively), indicating small meth-
odological and greater physiological variation as previ-
ously described [21].
All study data were stored in a digital workstation and
analyzed offline in random order by an investigator
blinded to the information of the day or the dose. In some
studies, image quality was insufficient for analysis, and
therefore, complete data could be recorded in 108/115
(94%) and 111/115 (97%) studies for CPT and CFR,
respectively.
Cold pressor test and CFR measurement
Baseline values were detected as an average of three sepa-
rate diameter and three flow velocity measurements. After
the baseline measurements, the subjects' right hand was
placed into ice-cold water for 120 s. During the hand
immersion, both diameter and flow velocity were meas-
ured in turn continuously. Epicardial coronary artery
diameter during the CPT is expressed as an average of the
measurements between 30 and 180 s and flow velocity as
an average of the measurements between 10 and 150 s
after placing the hand into the cold water. Minimum of
three measurements was used. After hand immersion,
there was at least 7 minutes interval before adenosine
infusion. Intravenous adenosine (adenosin item 5 mg/ml,
Item Development AB, Sweden) was infused at a rate of
0.14 mg/kg/min for 5 min and diameters and flow veloc-
ities were measured in turn continuously during the infu-
sion. The results of the measurements are expressed as an
average of three separate maximum diameter and flow
velocity measurements.
Blood samples
Venous blood samples were obtained for measurement of
total cholesterol, LDL cholesterol, HDL cholesterol and
triglyceride and glucose levels before the study. Serum
ethanol concentrations were determined after the high
dose of cognac using a standard photometric test (Modu-
lar P800, Roche Diagnostics GmbH, Mannheim, Ger-
many). The antioxidative capacity of EDTA plasma was
measured using a commercially available colorimetric
assay kit (ImAnOx, Immundiagnostik, Bensheim, Ger-
many) before drinking and after the high dose of cognac.
The assay was done and results calculated according to the
manufacturer's instructions. The lower detection limit of
the assay was 130 μmol/l. The intra-assay coefficients of
variation were 0.9% and 2.3% and the inter-assay coeffi-
cients were 1.63% and 2.43% for low and high levels,
respectively. Optical density was determined using the
Multiskan Ascent spectrophotometer at 450 nm (Thermo
Labsystems, Helsinki, Finland). All samples were col-
lected and stored in a similar manner and analyzed in ran-
domized order.
Statistical analysis
The data are presented as means ± SD. ANOVA for
repeated measurements was used to assess differences of
CPT and CFR between the doses. P-values indicating trend
were calculated using the repeated measures regression
analysis. A paired T-test was used to compare plasma anti-Cardiovascular Ultrasound 2008, 6:25 http://www.cardiovascularultrasound.com/content/6/1/25
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Epicardial coronary artery (LAD) diameter at baseline, during cold pressor test and adenosine infusion Figure 2
Epicardial coronary artery (LAD) diameter at baseline, during cold pressor test and adenosine infusion.Cardiovascular Ultrasound 2008, 6:25 http://www.cardiovascularultrasound.com/content/6/1/25
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oxidant levels before and after beverage ingestion. The
association of antioxidant capacity levels to CPT and CFR
measurements was tested assessing the Pearson correla-
tion coefficient between the differences in antioxidant
capacity levels and the differences in CFR before and after
drinking the beverages. P-values lower than 0.05 were
considered significant. The statistical analyses were done
using the Statistical Analysis System, SAS.
Results
CPT and CFR
Table 1 shows the effects of cognac on coronary mean
diastolic velocities and epicardial coronary artery diame-
ter during CPT and CFR measurement. There were no sig-
nificant difference between the before drinking and
moderate and high doses values in coronary reactivity (see
Table 2, Figures 4 and 5). The percentage increase in flow
velocity during CPT was 21 ± 26%, 9 ± 30% and 17 ± 29%
(p = NS) before drinking and after moderate and high
doses, respectively, compared to control day (23 ± 20%
and 25 ± 24%, p = NS). The corresponding values of CFR
were 4.4 ± 0.8, 4.1 ± 0.9, and 4.5 ± 1.2 (p = NS) on cognac
day, and 4.5 ± 1.4, and 4.0 ± 1.2 (p = NS) on control day.
Moreover, the epicardial vasodilation was not significatly
affected during CPT or CFR measurements before drink-
ing and after moderate and high doses.
Effects of cognac on rate pressure product are presented in
Figure 6. No significant changes were detected in the cor-
responding values at rest, during CPT or CFR measure-
ment before drinking, after moderate and high doses,
respectively.
Antioxidant capacity
Plasma antioxidant capacity increased from 301 ± 43.9
μmol/l to 320 ± 25.0 μmol/l by 7.6 ± 11.8%, (p = 0.01)
after cognac. Serum alcohol levels increased to 1.2 ±
0.2‰ after the full doses of cognac. There were no signif-
icant association between the increase of plasma antioxi-
Coronary flow velocity in the LAD obtained using pulsed- wave Doppler at baseline, during cold pressor test (CPT) and  adenosine infusion Figure 3
Coronary flow velocity in the LAD obtained using pulsed-
wave Doppler at baseline, during cold pressor test (CPT) and 
adenosine infusion.
Individual changes in coronary flow velocity reserve (CFR) before cognac [before], after a moderate dose (ethanol 0.5 g/kg)  [dose1] and a high dose (ethanol 1.0 g/kg) [dose2] Figure 4
Individual changes in coronary flow velocity reserve (CFR) before cognac [before], after a moderate dose (ethanol 0.5 g/kg) 
[dose1] and a high dose (ethanol 1.0 g/kg) [dose2]. Control 1 corresponds to the first measurement on a control day. Control 
2 corresponds to the measurement carried out 2 h after Control 1.Cardiovascular Ultrasound 2008, 6:25 http://www.cardiovascularultrasound.com/content/6/1/25
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dant capacity and coronary microcirculatory or epicardial
vasodilation during CPT or CFR measurements.
Discussion
We determined the effects of cognac on coronary reactiv-
ity, because epidemiological studies have indicated that
any alcohol containing beverage may be beneficial for the
heart [2]. In addition, many elderly patients with coronary
artery disease use cognac to releave cardiac symptoms. It
appeared that cognac had no effect on coronary reactivity
in healthy young men, but it increased plasma antioxi-
dant capacity. Furthermore, we found no association
between the increase of plasma antioxidant capacity and
coronary microcirculatory or epicardial vasodilation dur-
ing CPT or CFR measurements.
Non-significant changes in CPT and CFR measurements
reflect that cognac has no effect on coronary reactivity.
Cognac contains antioxidative polyphenols, although in
much smaller quantities than red wine [22], which is
known to improve CFR [3,5]. In a recent in vitro study, the
authors found that cognac induced vasodilation in the rat
aorta [8]. Moreover, polyphenols from cognac are able to
directly increase NO production without affecting O2
- and
Individual changes in hyperemia to baseline ratio of flow velocity in cold pressor test (CPT) Figure 5
Individual changes in hyperemia to baseline ratio of flow velocity in cold pressor test (CPT). before cognac [before], after a 
moderate dose (ethanol 0.5 g/kg) [dose1] and a high dose (ethanol 1.0 g/kg) [dose2]. Control 1 corresponds to the first meas-
urement on a control day. Control 2 corresponds to the measurement carried out 2 h after Control 1.
Table 1: Effects of cognac on mean diastolic velocity (MDV) and epicardial diameter of the LAD
Before drinking Moderate dose High dose
Rest CPT Adenosine Rest CPT Adenosine Rest CPT Adenosine
Cognac 
(n = 18)
MDV (m/s) 0.20 ± 0.05 0.23 ± 0.07 0.85 ± 0.17 0.24 ± 0.07 0.25 ± 0.08 0.93 ± 0.20 0.22 ± 0.07 0.24 ± 0.08 0.91 ± 0.18
Diameter 
(mm)
1.1 ± 0.4 1.2 ± 0.3 1.4 ± 0.4 1.1 ± 0.3 1.2 ± 0.3 1.4 ± 0.4 1.1 ± 0.3 1.1 ± 0.3 1.4 ± 0.4
Control 
(n = 16)
MDV (m/s) 0.21 ± 0.05 0.26 ± 0.06 0.93 ± 0.21 0.24 ± 0.06 0.29 ± 0.07 1.0 ± 0.25
Diameter 
(mm)
1.1 ± 0.3 1.2 ± 0.3 1.4 ± 0.3 1.1 ± 0.2 1.2 ± 0.2 1.5 ± 0.3
n = number of subjects in a group. No significant changes were detected in corresponding values at rest, during CPT and adenosine infusion before 
drinking, and after moderate and high doses, respectively.Cardiovascular Ultrasound 2008, 6:25 http://www.cardiovascularultrasound.com/content/6/1/25
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to enhance the capacity of bradykinin to produce NO in
human endothelial cells [23]. We could not verify these
findings in vivo in human coronary arteries. This can
probably be explained by the low polyphenol content of
cognac, which is insufficient to improve the reactivity to
CPT or CFR. Moreover, cognac may contain too low levels
of certain polyphenol subgroups, which are related to
improvement vasodilatory reactivity. For example, oligo-
meric procyanidins of red wine have been shown to
reduce vasoconstrictor endothelin-1 production in vitro
[24]. Other polyphenol groups mediating improving vas-
cular reactivity in vitro may include resveratrol, quercetin,
and catechins [25]. It is also possible that the changes after
cognac ingestion may be very small and, therefore, unde-
tectable by the measurements. However, the variability of
CPT or CFR measurements was moderate with low
intraobserver variability and greater physiological varia-
tion. On the other hand, ethanol may blunt the vasodila-
tory effects cognac polyphenols [26].
We tested coronary vasodilatory responses by two distinct
tests: CPT and CFR measurements. CPT is used as a phys-
iological measure to assess coronary reactivity. In the CPT,
the subject's hand or foot is placed in ice water, which pro-
duces a pain sensation. Nociception induces sympathetic
stimulation and release of adrenalin and noradrenalin
from the adrenal medulla [27-29], which increase heart
rate, arterial blood pressure and myocardial oxygen
demand. Increase in myocardial oxygen demand increases
coronary blood flow. Moreover, sympathetic stimulation
of α-adrenergic-receptors in the endothelium leads to the
release of NO, which facilitates vasodilation of the resist-
ance arteries [30]. Vasodilation of the resistance arteries
increases blood flow in the conductance arteries as well,
secondarily leading to vasodilation of the epicardial arter-
ies by shear stress, despite α-adrenergic-mediated con-
striction of smooth muscle cells. In the normal heart, the
net effect is vasodilation and increased coronary blood
flow. In patients with endothelial dysfunction, a distur-
bance in vasodilator mechanisms leads to insufficient
vasodilation, or vasoconstriction. CFR is defined as a ratio
of coronary blood flow during maximal pharmacologi-
cally-induced vasodilation to baseline blood flow. Adeno-
sine infusion is used to measure CFR, due to its capability
to induce the maximal dilation of small coronary arteries.
Secondarily, adenosine increases flow velocity in the epi-
cardial arteries, also leading to flow-mediated vasodila-
tion. Impairment of coronary artery reactivity as shown by
decreased CFR occurs in various cardiovascular diseases,
such as hypertension [12], diabetes [13], hypercholestero-
lemia [14] and coronary artery disease [15], and may be
due to impairment in vascular smooth muscle or
endothelial function or both.
Transthoracic echocardiography is a widely used non-
invasive bedside method for assessing CPT and CFR
Table 2: Effects of cognac on coronary flow velocity during CPT (hyperemia to baseline ratio) and coronary flow velocity reserve 
(CFR) in the LAD
Before drinking Before drinking vs. Moderate dose Before drinking vs High dose Trend
Cognac CPT 1.21 ± 0.26 -0.12 (-0.29 – 0.06) NS -0.03 (-0.19 – 0.13) NS P = 0.91
N = 18 CFR 4.4 ± 0.8 -0.29 (-0.83 – 0.24) NS 0.15 (-0.39 – 0.68) NS P = 0.71
Control 1 Control 2
Control CPT 1.23 ± 0.20 0.01 (-0.10 – 0.13) NS P = 0.64
N = 16 CFR 4.5 ± 1.0 -0.45 (-0.99 – 0.09) NS P = 0.85
Moderate and high dose correspond the amount of 0.5 g/kg and 1.0 g/kg ethanol, respectively. Data before drinking are presented mean ± SD. Data 
in the other columns are presented as the difference between the means (95% confidence intervals). The corresponding P value is from repeated 
analysis of variance. P-values indicating trend were calculated using the repeated measures regression analysis. Control 1 correspond the first 
measurement on control day. Control 2 correspond the measurement carried out 2 h after Control 1. N = number of subjects in a group. NS = not 
significant (P > 0.05)
Effects of cognac on rate pressure product Figure 6
Effects of cognac on rate pressure product. No significant 
changes were detected in the corresponding values at rest, 
during CPT or CFR measurement before drinking, after 
moderate and high doses, respectively. 0 = before drinking; 
Mod = moderate dose; High = high dose.Cardiovascular Ultrasound 2008, 6:25 http://www.cardiovascularultrasound.com/content/6/1/25
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responses and it correlates with invasive measurements
using a Doppler guide wire [31] and myocardial blood
flow quantified with PET [19]. This was the first time that
changes in both coronary flow velocity and epicardial cor-
onary artery diameter were measured simultaneously in a
clinical trial using transthoracic echocardiography.
Some limitations of the present study should be pointed
out. First, we studied young men only. However, as the
purpose of the study was to determine the acute effects of
cognac on coronary reactivity and plasma antioxidative
capacity, using a homogenous sample may have dimin-
ished the role of confounding factors. Moreover, athero-
sclerotic processes begin early in life, and the attenuation
of vasodilatory responses may be one of their early signs.
Therefore, it makes sense to study subjects in this age
group. Secondly, we saw marked variation in CFR (range
2.3 – 7.8) and moderate variability in totally reproduced
CFR studies (CV 11.5 ± 8.7%), but intra-observer variabil-
ity was low (2.6 ± 4.0%) indicating a small methodologi-
cal error and greater physiological variation.
In conclusion, despite an improvement in plasma antioxi-
dant capacity, cognac has no significant effect on coronary
reactivity.
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